BioNTech SE to Present Clinical Trial Data
Ticker: BNTX · Form: 6-K · Filed: May 21, 2024 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | May 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trials, data-release, biotech
TL;DR
BioNTech dropping new clinical trial data soon, watch this space.
AI Summary
On May 21, 2024, BioNTech SE announced that it will present clinical trial data for selected programs. The company, headquartered in Mainz, Germany, is a biopharmaceutical firm focused on infectious disease and cancer immunotherapies.
Why It Matters
The presentation of clinical trial data is crucial for BioNTech as it provides insights into the progress and potential of their drug development pipeline, impacting future investment and strategic decisions.
Risk Assessment
Risk Level: low — This filing is an announcement of upcoming data presentation and does not contain new financial or operational risks.
Key Players & Entities
- BioNTech SE (company) — Registrant
- May 21, 2024 (date) — Announcement date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to announce that BioNTech SE will present clinical trial data for selected programs.
When was this announcement made by BioNTech SE?
The announcement was made on May 21, 2024.
What is the principal executive office address of BioNTech SE?
The principal executive office address of BioNTech SE is An der Goldgrube 12, D-55131 Mainz, Germany.
Does BioNTech SE file annual reports under Form 20-F or Form 40-F?
BioNTech SE indicates that it files annual reports under Form 20-F.
What is the SIC code for BioNTech SE?
The Standard Industrial Classification (SIC) code for BioNTech SE is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 303 words · 1 min read · ~1 pages · Grade level 15.8 · Accepted 2024-05-21 16:36:58
Filing Documents
- form6-kascocurtainraiser21.htm (6-K) — 14KB
- a99_1240521xbntxascocurtai.htm (EX-99.1) — 36KB
- image_1.jpg (GRAPHIC) — 15KB
- 0001776985-24-000044.txt ( ) — 71KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On May 21, 2024, BioNTech SE ("BioNTech," or the "Company") announced that it will present clinical trial data for selected programs from the Company's diversified immuno-oncology pipeline at the American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago, Illinois, from May 31 to June 4, 2024. Moreover, in support of the Company's ongoing CAR-T cell and individualized mRNA programs, BioNTech will also present epidemiological and real-world data from two observational studies in patient populations for which product candidates are being developed in the Company's respective clinical programs. The press release is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Dr. Sierk Poetting Name Dr. Sierk Poetting Title Chief Operating Officer Date May 21, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024